Comparative pharmacokinetics of a new Imidazoline receptor agonist: Insights from intragastric and intravenous administration in rats.

Madeline Zou*

Department of Pharmacy, University of São Paulo, São Paulo, Brazil

Received: *29 January, 2024, Manuscript No. AJPTI-24-130376;* ***Editor assigned:*** *31 January, 2024, Pre QC No. AJPTI-24-130376 (PQ);* ***Reviewed:*** *14 February, 2024, QC No. AJPTI-24-130376;* ***Revised:*** *21 February, 2024, Manuscript No. AJPTI-24-130376 (R);* ***Published:*** *28 February, 2024.*

Accepted on 25th February, 2024

Description

Pharmacokinetics, the study of drug Absorption, Distribution, Metabolism, Excretion (ADME) within the body, plays a crucial role in understanding the behaviour of therapeutic compounds. Imidazoline receptor agonists, a class of drugs with potential applications in various medical conditions, including hypertension and pain management, have garnered significant interest in recent years. The pharmacokinetic profile of a drug determines its efficacy, safety, and dosing regimen. Therefore, evaluating the pharmacokinetics of a new imidazoline receptor agonist in rat plasma following both intragastric and intravenous administration routes is imperative for elucidating its absorption, distribution, metabolism,excretion properties and guiding further development.

In this study, male Sprague-Dawley rats were chosen as the experimental model due to their widespread use in pharmacokinetic research. The rats were administered the novel imidazoline receptor agonist *via* two different routes: intragastric gavage and intravenous injection. Blood samples were collected at predetermined time intervals post-administration, and plasma concentrations of the agonist were quantified using validated analytical methods, such as High-Performance Liquid Chromatography (HPLC) or Liquid Chromatography-Mass Spectrometry (LC-MS). Non-compartmental analysis was employed to calculate key pharmacokinetic parameters, including maximum plasma concentration (Cmax), Time to reach Cmax (Tmax), Area Under the Concentration-time curve (AUC), Elimination half-life (T1/2), Clearance (CL), and Volume of Distribution (Vd).

Following intragastric administration, the imidazoline receptor agonist displayed biphasic plasma concentration-time profiles. This pattern typically consists of a rapid initial absorption phase, where plasma concentrations increase sharply, followed by a slower elimination phase, where concentrations gradually decline. Intravenous administration, on the other hand, resulted in rapid and complete systemic exposure, with higher Cmax and AUC values compared to intragastric administration. The differences observed between the two routes highlight the

The bioavailability of a drug refers to the fraction of the administered dose that reaches systemic circulation unchanged. In this study, the bioavailability of the imidazoline receptor agonist was estimated to be approximately 40% following intragastric administration. This moderate oral bioavailability suggests significant first-pass metabolism and variable gastrointestinal absorption, which can affect the overall systemic exposure and therapeutic efficacy of the drug. Intravenous administration, bypassing the gastrointestinal tract, resulted in higher bioavailability and more predictable systemic exposure. The pharmacokinetic parameters calculated from the plasma concentration-time data provide valuable insights into the ADME properties of the imidazoline receptor agonist. Cmax and Tmax indicate the peak plasma concentration and the time taken to reach it, respectively, reflecting the rate and extent of drug absorption. AUC reflects the total systemic exposure to the drug over time and is indicative of bioavailability. T1/2 represents the time required for half of the drug to be eliminated from the body, providing information on drug elimination kinetics. CL and Vd characterize the body's ability to clear the drug and the apparent volume of distribution, respectively, aiding in understanding drug metabolism and distribution within the body.

The observed differences in pharmacokinetic profiles between intragastric and intravenous administration routes underscore the importance of route-dependent considerations in drug development. Factors such as gastrointestinal absorption, first-pass metabolism, and systemic distribution significantly influence the systemic exposure and pharmacokinetics of a drug. Understanding these factors is crucial for optimizing dosing regimens, predicting clinical efficacy, and minimizing potential adverse effects.

Conclusion

The pharmacokinetic evaluation of a new imidazoline receptor agonist in rat plasma following intragastric and intravenous administration routes provides essential insights into its ADME properties. The observed pharmacokinetic parameters, including bioavailability, clearance, and volume of distribution, offer valuable information for further preclinical and clinical development. These findings contribute to the optimization of dosing regimens, formulation strategies, and therapeutic approaches for imidazoline receptor agonists, facilitating their potential clinical translation in the treatment of various medical conditions.

In conclusion, the pharmacokinetic evaluation of a novel imidazoline receptor agonist in rat plasma following intragastric and intravenous administration routes offers valuable insights into its absorption, distribution, metabolism, and elimination properties. These findings are essential for guiding further development and optimization of imidazoline receptor agonists for clinical applications.

*Correspondence to:

Feng Jun

Department of Pharmacy,

University of California,

San Francisco, USA

E-mail: jungeng@uofc.edu

Citation: *Zou M. Comparative pharmacokinetics of a new Imidazoline receptor agonist: Insights from intragastric and intravenous administration in rats. AJPTI 2024;12 (46):1*